CTI BioPharma Corp.’s recently launched Vonjo can increase hemoglobin levels and reduce transfusion dependence in anemic myelofibrosis patients according to new data from the firm, which could support its expanded use.
Vonjo (pacritinib) first won a US accelerated approval for the treatment of myelofibrosis with severe thrombocytopenia early this year based...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)